Allergan Breast Implant Lawsuit in California

California plaintiffs may file in MDL 2921 (In re: Allergan BIOCELL Textured Breast Implant Products Liability Litigation) in the U.S. District Court for the District of New Jersey before Judge Brian R. Martinotti. California represents the largest single-state plaintiff pool in MDL 2921 given its outsized share of U.S. cosmetic surgery volume. Plaintiffs may alternatively pursue claims in California Superior Court, where product liability standards under the consumer expectations test or risk-utility balancing apply; California courts use the Kelly-Frye standard for novel scientific evidence rather than Daubert.

California's personal injury statute of limitations is two years under Code of Civil Procedure § 335.1. For latent injuries such as BIA-ALCL, the discovery rule tolls the clock from the date the plaintiff knew or reasonably should have known of the injury and its cause — typically the BIA-ALCL diagnosis date. California's delayed-discovery doctrine is well-developed and plaintiff-favorable. Claims against Allergan (now an AbbVie subsidiary) must also account for the July 2019 FDA Class I recall date as a potential inquiry-notice anchor.

Within the MDL, cases are venued in Newark before Judge Martinotti and Magistrate Judge Leda Dunn Wettre. In state court, Los Angeles Superior Court (Stanley Mosk Courthouse) handles the majority of California BIOCELL cases; the court's Complex Civil Litigation Program in Dept. 1 or coordinated JCCP proceedings may apply if filings reach coordination thresholds. San Diego Superior Court and Orange County Superior Court are additional active venues for Southern California plaintiffs.

California's exposure concentration tracks its cosmetic surgery market: Los Angeles County (Beverly Hills, Santa Monica, Brentwood surgical corridors), Orange County, San Diego, and the San Francisco Bay Area account for the dominant share of Natrelle 410 and Natrelle 133 BIOCELL placements from 2005–2019. California plastic surgery practice patterns, including high rates of textured implant preference among certain surgeons during the relevant period, are a key fact-development area in discovery.